Olmiwave-20 AMH Tablet is a combination antihypertensive medication containing Olmesartan Medoxomil (20 mg), Amlodipine (5 mg), and Hydrochlorothiazide (12.5 mg). This formulation is indicated for the management of hypertension, providing effective blood pressure control through complementary mechanisms of action. Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) that inhibits vasoconstriction and aldosterone secretion, thereby reducing peripheral vascular resistance. Amlodipine, a calcium channel blocker, promotes vasodilation by inhibiting calcium ion influx into vascular smooth muscle and cardiac muscle, further aiding in blood pressure reduction. Hydrochlorothiazide is a thiazide diuretic that facilitates sodium and water excretion, decreasing plasma volume and cardiac output. The combination of these agents offers synergistic antihypertensive effects, improving efficacy while potentially minimizing adverse effects associated with higher doses of individual drugs. Olmiwave-20 AMH is suitable for patients who require multiple drug therapy to achieve target blood pressure levels. It is essential to monitor renal function, electrolyte balance, and blood pressure regularly during treatment. Contraindications include hypersensitivity to any component, anuria, and severe renal or hepatic impairment. Use with caution in patients with electrolyte imbalances or gout.